HIV Prevention

;

Support for Rhode Island’s H 8041 “An Act Relating to Insurance—Prescription Drug Benefits”

Apr 4, 2024

We voice our strong support for Rhode Island’s H 8041 (“An Act Relating to Insurance—Prescription Drug Benefits”) which stipulates that, when calculating an enrollee’s overall contribution to any out-of-pocket maximum or any cost-sharing requirement under a health plan, an insurer or pharmacy benefit manager shall include any amounts paid by the enrollee or paid on behalf of the enrollee by another person. We thank you for considering this legislation and are pleased to offer our support.

read more

Testimony on the selection of drugs for referral to MD stakeholder council

Mar 20, 2024

We believe Maryland policymakers should focus on those issues that directly impact patients, such as PBM regulation and reform, standard plan designs with reasonable deductibles and nominal copays, and ensuring copay assistance counts. We note that the General Assembly is currently considering HB 879, legislation that would ensure that copay assistance programs will count toward deductibles and out-of-pocket maximums, and the Senate is considering SB 595.

read more

Testimony on the IL Health Care Availability and Access Board Act (HB 4472)

Mar 12, 2024

We believe policymakers should focus on those issues that directly impact patients, such as PBM regulation and reform, standard plan designs with reasonable deductibles and nominal copays, and ensuring copay assistance counts. We realize that Illinois has taken many of these steps already, and that Illinois policymakers are advocating for change at the national level, too, but more can be done.

read more

Oppose domestic HIV programs cuts of $767 million & proposed amendments

Nov 14, 2023

The HIV+Hepatitis Policy Institute urges all members of the House of Representatives to oppose the FY24 Labor HHS Appropriations Bill (HR 5894) due to the $767 million in cuts to HIV domestic prevention and treatment programs, massive cuts to other related programs, and the many damaging social policy riders that are directed to the communities most impacted by HIV.

read more

Support for MA state bills to address barriers to HIV prevention medication

Nov 14, 2023

On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of H.1085/S.619: An Act to address barriers to HIV prevention medication. We need to ensure that everyone is able to benefit from the results of the latest scientific innovations in HIV prevention.  We urge the passage of this important bill to ensure that all Bay Staters using commercial insurance can access PrEP without a financial barrier or delay. 

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest